MK 571

CAS No. 115104-28-4

MK 571( L-660711 | L660711 | MK-571 )

Catalog No. M21561 CAS No. 115104-28-4

MK 571 is an orally active antagonist of CysLT1 receptor .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 74 Get Quote
10MG 115 Get Quote
25MG 235 Get Quote
50MG 348 Get Quote
100MG 518 Get Quote
500MG 1134 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    MK 571
  • Note
    Research use only, not for human use.
  • Brief Description
    MK 571 is an orally active antagonist of CysLT1 receptor .
  • Description
    MK 571 is an orally active antagonist of CysLT1 receptor.
  • In Vitro
    Cell Viability Assay Cell Line:RBL-2H3 cells, human LAD2 mast cells Concentration:15 μM Incubation Time:1 h Result:Inhibited S1P secretion by vector and SphK1 transfected RBL-2H3 cells, whereas it did not affect uptake and intracellular conversion of [3H]Sph to S1P. Inhibited Fluo-3 efflux, inhibited S1P export by LAD2 cells, and blocked Ag-stimulated release of S1P.
  • In Vivo
    Animal Model:Hyperreactive rats (male and female, 200-400 g, pretreated intravenously with 3μg/kg methysergide, 5 min before antigen chdlenge)Dosage:0.5, 0.15, and 0.05 mg/kgAdministration:Orally, once, 1 or 4 h before challengeResult:Produced dose-dependent inhibition of the duration of antigen-induced dyspnea, with ED50 values of 0.13 (95% confidence interval (CI), 0.03-0.62) and 0.11 (95% CI, 0.009-1.47) mg/kg, respectively. MK-571 was even more active when administered orally as a suspension in 1% Methocel (4 h pretreatment), with an ED50 of 0.068 (95% CI, 0.83-0.14) mg/kg.Animal Model:Csnscisus squirrel msnkeys Dosage:0.1, 0.5, and 1 mg/kg Administration:Orally, once, 2 h prior to challenge with Ascaris antigenResult:Produced significant inhibition of the bronchoconstriction at 0.5 mg/kg, produced significant inhibition of the increases in RL and decreases in Cdyn at 1 mg/kg.Animal Model:FVB (Friend virus B-type) mice (Mrp4–/– and WT, 6 weeks old, exposed to chronic hypoxia (10% O2) in a ventilated chamber for 28 days)Dosage:0, 5, and 25 mg/kg Administration:Orally, daily, for 2 more weeks, maintain in hypoxic conditionsResult:Showed reversal of hypoxic pulmonary hypertension (PH), and mice were protected from hypoxic PH. MK-571-treated mice displayed lower RVSP and Fulton index and a decrease in the medial thickening of small pulmonary arteries and arterioles.
  • Synonyms
    L-660711 | L660711 | MK-571
  • Pathway
    Immunology/Inflammation
  • Target
    LTR
  • Recptor
    CysLTR1
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    115104-28-4
  • Formula Weight
    515.09
  • Molecular Formula
    C26H26ClN2NaO3S2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CN(C)C(=O)CCSC(SCCC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Lynch K R O'Neill G P Liu Q et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor[J]. Nature 1999 399(6738):789-793.
molnova catalog
related products
  • MK 571

    MK 571 is an orally active antagonist of CysLT1 receptor .

  • Ubenimex

    Bestatin (Ubenimex) is a competitive aminopeptidase inhibitor.

  • CP-105696

    CP-105696 is a potent and selective leukotriene B4 (LTB4) receptor antagonist used to study allograft rejection.